Musculoskeletal Safety Outcomes of Patients Receiving Daptomycin with HMG-CoA Reductase Inhibitors

Bland, Christopher M.; Bookstaver, P. Brandon; Zhiqiang, Liang; Dunn, Brianne L.; Rumley, Kathey Fulton

doi:10.1128/aac.02910-14

Cited by 34 publications

(62 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it is not suitable to exceed the dose of 6 mg/kg in patients with obesity and creatinine clearance less than 50 ml/min (Gutiérrez Urbón et al 2013). Daptomycin and statins when administered together caused creatine phosphokinase elevations, muscle pain and muscle weakness (Bland et al 2014). Even when exposed to daptomycin of 100-fold MIC concentration, some Staphylococcus aureus SA113 survived.…”

Section: Issues To Overcome and Solutionsmentioning

confidence: 98%

Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles

Patel

Ahmed

Eswari

2015

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Infectious diseases impose serious public health burdens and often have devastating consequences. The cyclic lipopeptides elaborated by bacteria Bacillus, Paenibacillus, Pseudomonas, Streptomyces, Serratia, Propionibacterium and fungus Fusarium are very crucial in restraining the pathogens. Composed of a peptide and a fatty acyl moiety these amphiphilic metabolites exhibit broad spectrum antimicrobial effects. Among the plethora of cyclic lipopeptides, only selective few have emerged as robust antibiotics. For their functional vigor, polymyxin, daptomycin, surfactin, iturin, fengysin, paenibacterin and pseudofactin have been integrated in mainstream healthcare. Daptomycin has been a significant part of antimicrobial arsenal since the past decade. As the magnitude of drug resistance rises in unprecedented manner, the urgency of prospecting novel cyclic lipopeptides is being perceived. Intense research has revealed the implication of these bioactive compounds stretching beyond antibacterial and antifungal. Anticancer, immunomodulatory, prosthetic parts disinfection and vaccine adjuvancy are some of the validated prospects. This review discusses the emerging applications, mechanisms governing the biological actions, role of genomics in refining structure and function, semi-synthetic analog discovery, novel strain isolation, setbacks etc. Though its beyond the scope of the current topic, for holistic purpose, the role of lipopeptides in bioremediation and crop biotechnology has been briefly outlined. This updated critique is expected to galvanize innovations and diversify therapeutic recruitment of microbial lipopeptides.

show abstract

Section: Issues To Overcome and Solutionsmentioning

confidence: 98%

Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles

Patel

Ahmed

Eswari

2015

World J Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…Bland et al's study compared 220 patients receiving daptomycin (49 with statins vs 171 without statins) and did not find statistically significant differences in frequencies of myalgia (6.1% vs 2.9%, respectively; p = 0.38), CK levels of >1,000 U/ liter (10.2% vs 5.3%, respectively; p = 0.32), or therapy discontinuation due to CK elevations with concurrent myalgia (6.1% vs 3.5%, respectively; p = 0.42). [21]. Berg et al's study compared 498 patients receiving daptomycin (63 with statins and 384 without statins) and did not find a statistically significant difference in frequency of CK elevation (Hazard Ratio, 0.44; 95% Confidence Interval, 0.14-1.40; p = 0.17) [22].…”

Section: Statins Interactions With Daptomycinmentioning

confidence: 99%

“…The prescribing information for daptomycin recommends considering suspending statin during treatment with daptomycin [49]. To date, studies have not found a higher risk of adverse outcomes with concomitant administration; however, these studies are retrospective and could be underpowered [21][22][23][24][25].…”

Section: Statins Interactions With Daptomycinmentioning

confidence: 99%

See 1 more Smart Citation

An updated review of interactions of statins with antibacterial and antifungal agents

Eljaaly¹,

Alshehri²

2017

J Transl Sci

View full text Add to dashboard Cite

Numerous antimicrobial agents interact with statins. It is important to prevent these drug interactions and resulting statin toxicity and/or reduced efficacy. We review and highlight major drug-drug interactions between statins and antibacterial and antifungal agents; interactions with antiviral agents were not considered. Daptomycin interacts with statins via additive skeletal muscle toxicity. One possibility is to discontinue statins during daptomycin therapy, though no retrospective studies to date have shown a statistically significant elevation of adverse outcome risk. Multiple doses of rifampin induce cytochrome P450 (CYP), particularly 3A4 and 2C9, resulting in reduced systemic exposures to all statins, except rosuvastatin, for which the response was variable. Macrolide antibiotics are inhibitors of CYP3A4 and organic anion-transporting polypeptide-1B1. Azithromycin has the fewest drug interactions, while clarithromycin and erythromycin increase systemic exposure to all statins except rosuvastatin and fluvastatin. Azole antifungals are CYP450 inhibitors. Itraconazole and posaconazole are strong CYP3A4 inhibitors and mainly affect simvastatin, lovastatin, and atorvastatin, while fluconazole is an inhibitor of CYP2C9 and potentially CYP2C19 and mainly affects fluvastatin; however, risk cannot be ruled out with rosuvastatin.

show abstract

“…Concomitant use of other agents that may cause myopathy, including inhibitors of 3-hydroxy-3-methyl-glutarylcoenzyme A reductase (statins), may increase the risk of increasing the levels of creatinine phosphokinase and should be avoided if possible. 15 Data are limited on the coadministration of daptomycin and statins, and results of a recent retrospective observational study 24 indicated a slightly higher incidence of elevations in creatinine phosphokinase level when combination therapy was used (6.1% vs 2.9%; P = .38). Elevations in phosphokinase level rarely result in discontinuation of therapy.…”

Section: Alternative Treatments For Mrsa Infectionsmentioning

confidence: 99%

Treating Central Catheter–Associated Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Beyond Vancomycin

Holt

Thompson-Brazill

Sparks

et al. 2016

Critical Care Nurse

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus is a frequent cause of hospital-associated infections, including central catheter-associated bacteremia. Vancomycin has been the drug of choice for treating this type of bacteremia for decades in patients who have no contraindications to the antibiotic. However, resistance to vancomycin is an emerging problem. Newer antibiotics approved by the Food and Drug Administration have activity against methicillin-resistant S aureus. Some of the antibiotics also have activity against strains of S aureus that are intermediately susceptible or resistant to vancomycin. This article uses a case study to highlight the clinical signs of vancomycin failure and describes the indications for and appropriate use of alternative antimicrobials such as ceftaroline, daptomycin, linezolid, tigecycline, and telavancin. (Critical Care Nurse. 2016;36[4]:46-57) 1 S aureus is both a commensal skin organism and a pathogen. Colonization can lead to infection when a breach occurs in the skin or mucosal defense systems because of trauma or common procedures This article has been designated for CE contact hour(s). The evaluation tests your knowledge of the following objectives: 1. Discuss the signs of vancomycin failure in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) central catheter-associated bacteremia 2. Describe the indications for use of daptomycin and ceftaroline for treatment of MRSA central catheter-associated bacteremia 3. Verbalize at least 2 nursing interventions that help prevent MRSA central catheter-associated bacteremia

show abstract

Musculoskeletal Safety Outcomes of Patients Receiving Daptomycin with HMG-CoA Reductase Inhibitors

Cited by 34 publications

References 19 publications

Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles

Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles

An updated review of interactions of statins with antibacterial and antifungal agents

Treating Central Catheter–Associated Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Beyond Vancomycin

Contact Info

Product

Resources

About